Diamedica Inc. announce that Mark Robbins, Ph.D., J.D., has joined as Vice President, Clinical and Regulatory Affairs to oversee DiaMedica's clinical programs. Dr. Robbins has over 30 years of experience in biopharmaceutical drug development with broad therapeutic experience in endocrine/metabolic, cardiology, neurology, dermatology, and oncology. Dr. Robbins was most recently President & CEO of Kodiak Strategic Consultants and President & CEO of Tychon Bioscience Inc.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.47 USD | +8.44% |
|
+19.66% | +22.18% |
Jul. 01 | DiaMedica Therapeutics Inc. announced that it has received $11.8 million in funding | CI |
Jun. 27 | Transcript : DiaMedica Therapeutics Inc. - Special Call |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.18% | 148M | |
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- DMAC Stock
- News DiaMedica Therapeutics Inc.
- Diamedica Inc. Appoints Dr. Mark Robbins as Vice President, Clinical and Regulatory Affairs